ES2051686T3 - Metodo para preparar factor antihemofilico (ahf) por precipitacion en frio y para mejorar la solubilidad del producto de ahf recuperado. - Google Patents

Metodo para preparar factor antihemofilico (ahf) por precipitacion en frio y para mejorar la solubilidad del producto de ahf recuperado.

Info

Publication number
ES2051686T3
ES2051686T3 ES86115463T ES86115463T ES2051686T3 ES 2051686 T3 ES2051686 T3 ES 2051686T3 ES 86115463 T ES86115463 T ES 86115463T ES 86115463 T ES86115463 T ES 86115463T ES 2051686 T3 ES2051686 T3 ES 2051686T3
Authority
ES
Spain
Prior art keywords
ahf
cold precipitation
fibrinogen
fibronectin
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES86115463T
Other languages
English (en)
Inventor
Maria Erlinda C Sarno
Clifford R Graf
Rodolfo A Vasquez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25168481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2051686(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter International Inc filed Critical Baxter International Inc
Application granted granted Critical
Publication of ES2051686T3 publication Critical patent/ES2051686T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)

Abstract

SE PONE A PUNTO UN METODO MEJORADO PARA RECUPERACION DE FACTOR ANTIHEMOFILICO (AHF) A PARTIR DE PLASMA SANGUINEO CRIOPRECIPITADO. EL METODO MEJORADO INCORPORA LA ADICION DE UNA FUENTE DE ION CALCIO DURANTE LA ETAPA DE PRECIPITACION EN FRIO DE CONTAMIENANTES DE FIBRINOGENO Y FIBRONECTINA, ASI COMO LA ADICION DE POLIETILENGLICOL (PEG) EN UNA O VARIAS ETAPAS DEL PROCESO DE RECUPERACION. EL PEG PUEDE AÑADIRSE DURANTE LA PRECIPITACION EN FRIO DE FIBRINOGENO Y FIBRONECTINA, DURANTE LA PRECIPITACION DEL AHF, O ANTES DE LA FILTRACION DE LA SOLUCION DEL AHF. EL METODO DE LA PRESENTE INVENCION DA LUGAR A UN PRODUCTO AHF FINAL QUE TIENE UNA SOLUBILIDAD MUY AUMENTADA, MAYOR ACTIVIDAD ESPECIFICA Y UN CONTENIDO MENOR DE FIBRINOGENO Y FIBRONECTINA.
ES86115463T 1985-11-08 1986-11-07 Metodo para preparar factor antihemofilico (ahf) por precipitacion en frio y para mejorar la solubilidad del producto de ahf recuperado. Expired - Lifetime ES2051686T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US79655985A 1985-11-08 1985-11-08

Publications (1)

Publication Number Publication Date
ES2051686T3 true ES2051686T3 (es) 1994-07-01

Family

ID=25168481

Family Applications (1)

Application Number Title Priority Date Filing Date
ES86115463T Expired - Lifetime ES2051686T3 (es) 1985-11-08 1986-11-07 Metodo para preparar factor antihemofilico (ahf) por precipitacion en frio y para mejorar la solubilidad del producto de ahf recuperado.

Country Status (9)

Country Link
US (1) US4739039A (es)
EP (1) EP0221566B1 (es)
JP (1) JPH0822879B2 (es)
AT (1) ATE79266T1 (es)
AU (1) AU6487286A (es)
CA (1) CA1293941C (es)
DE (1) DE3686390T2 (es)
ES (1) ES2051686T3 (es)
ZA (1) ZA868516B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8505882D0 (en) * 1985-03-07 1985-04-11 Central Blood Lab Authority Purification of blood coagulation factor viii
DE3806562A1 (de) * 1988-03-01 1989-09-14 Alpha Therapeutic Gmbh Zweikammerspritze mit einer fuellung aus aktivitaetsempfindlichem humanen protein als wirkstoff
DK0399321T3 (da) * 1989-05-24 1993-08-09 Miles Inc Gelfiltrering af varmebehandlet faktor VIII
DE3926034C3 (de) * 1989-08-07 1996-11-21 Behringwerke Ag Verfahren zur Herstellung eines stabilen Faktors VIII
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
US5259971A (en) * 1992-03-02 1993-11-09 Cryolife, Inc. Method of preparing fibrinogen
US5330974A (en) * 1993-03-01 1994-07-19 Fibratek, Inc. Therapeutic fibrinogen compositions
US5523893A (en) * 1994-08-24 1996-06-04 Northrop Grumman Corporation Strain free temperature-compensated optical mounts
GB9424732D0 (en) * 1994-12-08 1995-02-08 Common Services Agency Heat treated blood plasma proteins
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
CA2634664C (en) 1999-02-22 2011-08-09 University Of Connecticut Novel albumin-free factor viii formulations
NZ593190A (en) 2008-11-07 2013-01-25 Baxter Int Factor viii formulations
KR102356757B1 (ko) 2013-10-18 2022-02-03 노바셉 이큅먼트 솔루션즈 단백질 정제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE713764A (es) * 1967-05-01 1968-09-16 Baxter Travenol Lab
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
GB1507198A (en) * 1974-04-12 1978-04-12 Squibb & Sons Inc Antihemophilic factor
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
CA1054052A (en) * 1976-08-14 1979-05-08 Edward Shanbrom Simplified method for preparation of high yield, high purity factor viii concentrate
US4104266A (en) * 1977-04-14 1978-08-01 American National Red Cross Method for preparation of antihemophilic factor
FR2460305A2 (fr) * 1979-06-29 1981-01-23 Merieux Inst Procede de preparation d'un concentre de facteur viii
US4289691A (en) * 1980-01-18 1981-09-15 The Canadian Red Cross Society Method of obtaining intermediate purity factor VIII
US4386068A (en) * 1980-02-26 1983-05-31 Cutter Laboratories, Inc. Antihemophilic factor concentrate and method for preparation
US4294826A (en) * 1980-05-07 1981-10-13 Armour Pharmaceutical Company Process for the preparation of highly purified antihemophilic factor
AT369263B (de) * 1980-08-27 1982-12-27 Immuno Ag Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates
US4406886A (en) * 1983-01-14 1983-09-27 University Patents, Inc. Purification of antihemophilia factor VIII by precipitation with zinc ions
DE3318521A1 (de) * 1983-05-20 1984-11-22 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate

Also Published As

Publication number Publication date
JPH0822879B2 (ja) 1996-03-06
DE3686390T2 (de) 1993-03-04
ZA868516B (en) 1987-08-26
ATE79266T1 (de) 1992-08-15
EP0221566A3 (en) 1987-10-07
US4739039A (en) 1988-04-19
AU6487286A (en) 1987-05-14
DE3686390D1 (de) 1992-09-17
EP0221566A2 (en) 1987-05-13
EP0221566B1 (en) 1992-08-12
CA1293941C (en) 1992-01-07
JPS62181220A (ja) 1987-08-08

Similar Documents

Publication Publication Date Title
ES2051686T3 (es) Metodo para preparar factor antihemofilico (ahf) por precipitacion en frio y para mejorar la solubilidad del producto de ahf recuperado.
CA1074698A (en) Method of collecting anti-hemophilic factor viii from blood and blood plasma
DE69831684D1 (de) Verfahren zur herstellung von virusfreien thrombin zur bereitung von fibrinkleber aus menschlichem plasma-pool
DE60014047D1 (de) Verfahren zur reinigung von milchsäure auf industrieller basis
DE69002427D1 (de) Verfahren zur herstellung eines konzentrats des faktor viii-von willebrand-faktor-komplexes der blutgerinnung aus vollplasma.
IL122665A0 (en) Method and apparatus for inactivating contaminants in blood products
EP0125520A3 (en) A process and a plant for the recovery of one or more constituents from a gas mixture
ES477942A1 (es) Procedimiento para el tratamiento de soluciones acuosas impuras de oxido de etileno.
GR3026053T3 (en) Recovery of citric acid from impure process streams by addition of strong acids and salts thereof.
KR880000465A (ko) 순수한 알부민의 제조방법
SE8104482L (sv) Forfarande for framstellning av ett faktor viii (ahf)-hogkoncentrat
DE69311337D1 (de) Verfahren zur Reinigung von Proteinen
DE69010442T2 (de) Reinigung von 1,1-Dichlor-1-fluorethan.
FI915813A0 (fi) Menetelmä luonnollisesti tuotetun kymosiinin talteenottamiseksi
FR2632302B1 (fr) Procede de recuperation d'acide citrique a partir d'une liqueur en contenant
ES2053619T3 (es) Procedimiento para la fabricacion de un factor antihemofilico de gran pureza y libre de virus mediante cromatografia.
EP0237981A3 (de) Verfahren zur Herstellung eines den Blutgerinnungsfaktor VIII enthaltenden, sterilen Präparates
ATE35533T1 (de) Verfahren zur rueckgewinnung von reiner benzoesaeure.
DE69525948D1 (de) Verfahren zur wiedergewinnung von zitronensäure
JPH0345080B2 (es)
TW254947B (en) An improved process for hemoglobin purification
ATE138046T1 (de) Verfahren zur entfernung von abgelagerten verunreinigungen in einem organischen strom zur erzeugung reiner phosphorsäure
JPS6236487B2 (es)
EP0238986A3 (de) Verfahren zur Herstellung eines den Blutgerinnungsfaktor VIII in ankonzentrierter Form enthaltenden Präparates
ES8500059A1 (es) Procedimiento para la produccion de concentrado de factor antihemofilico.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 221566

Country of ref document: ES